DNA repair pathways in human multiple myeloma: Role in oncogenesis and potential targets for treatment

Cell Cycle

Volumn 12, Issue 17, 2013, Pages 2760-2773

  Gourzones Dmitriev, Claire ^a,b   Kassambara, Alboukadel ^a,b   Sahota, Surinder ^c   Rème, Thierry ^a,b   Moreaux, Jérôme ^a,b   Bourquard, Pascal ^d   Hose, Dirk ^e   Pasero, Philippe ^f   Constantinou, Angelos ^f   Klein, Bernard ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d NÎMES UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f CNRS   (France)

Author keywords

Bortezomib; DNA repair; Drug resistance; Genetic instability; Homologous recombination; Melphalan; Multiple myeloma; Non homologous end joining

Indexed keywords

BORTEZOMIB; DACARBAZINE; DEXAMETHASONE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; MELPHALAN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REPLICATION FACTOR A; THALIDOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; DNA CROSS LINKING; DNA END JOINING REPAIR; DNA REPAIR; DNA REPLICATION; DNA TRANSCRIPTION; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; IN VITRO STUDY; MISMATCH REPAIR; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PROTEIN EXPRESSION; REVIEW;

BORTEZOMIB; DNA REPAIR; DRUG RESISTANCE; GENETIC INSTABILITY; HOMOLOGOUS RECOMBINATION; MELPHALAN; MULTIPLE MYELOMA; NON-HOMOLOGOUS END JOINING;

CARCINOGENESIS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA;

EID: 84883583757     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25951     Document Type: Review

References (151)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138
2. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd. A longterm study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564-9; PMID:11856795; http://dx.doi.org/10.1056/NEJMoa01133202
3. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113:5412-7; PMID:19179464; http://dx.doi.org/10. 1182/blood-2008-12-194241
4. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8:479-91; PMID:21522124; http://dx.doi.org/10.1038/nrclinonc.2011.63
5. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113:5418-22; PMID:19234139; http://dx.doi.org/10.1182/blood-2008-12-195008
6. Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, Kumar SK. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013; 27:1738-44; PMID:23515097; http://dx.doi.org/10.1038/ leu.2013.86
7. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362-9; PMID:16571879; http://dx.doi.org/10.1056/NEJMoa054494
8. Zojer N, Ludwig H, Fiegl M, Stevenson FK, Sahota SS. Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma. Blood 2003; 101:4137-9; PMID:12531815; http://dx.doi.org/10. 1182/blood-2002-09-2825
9. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 1999; 104:131-7; PMID:10027725; http://dx.doi.org/10.1046/j.1365-2141.1999.01136.x
10. Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD Jr., Barlogie B, Zhou Y, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011; 96:87-95; PMID:20884712; http://dx.doi.org/10.3324/haematol.2010.030296
11. Greipp PR, Katzmann JA, O'Fallon WM, Kyle RA. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72:219-23; PMID:3291982
12. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, Oken MM, Kay NE, Van Ness B, Kyle RA. Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91:2501-7; PMID:9516151
13. Paiva B, Vidriales M-B, Montalban M-A, Perez JJ, Gutierrez NC, Rosinol L, Martinez-Lopez J, Mateos MV, Cordon L, Oriol A, et al. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005 trials. Am J Pathol 2012; 181:1870-8; PMID:22974582; http://dx.doi.org/10.1016/j.ajpath.2012.07.020
14. Nussenzweig A, Nussenzweig MC. Origin of chromosomal translocations in lymphoid cancer. Cell 2010; 141:27-38; PMID:20371343; http://dx.doi.org/10.1016/ j.cell.2010.03.016
15. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64:1546-58; PMID:14989251; http://dx.doi.org/10.1158/0008-5472.CAN-03-2876
16. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119:2100-5; PMID:22234687; http://dx.doi.org/10.1182/blood-2011-11-390658
17. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12:335-48; PMID:22495321; http://dx.doi.org/10. 1038/nrc3257
18. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA endjoining pathway. Annu Rev Biochem 2010; 79:181-211; PMID:20192759; http://dx.doi.org/10.1146/annurev.biochem.052308.093131
19. Wilson PC, de Bouteiller O, Liu YJ, Potter K, Banchereau J, Capra JD, Pascual V. Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes. J Exp Med 1998; 187:59-70; PMID:9419211; http://dx.doi.org/10.1084/jem.187.1.59
20. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122:3456-63; PMID:23023717; http://dx.doi.org/10.1172/JCI61188
21. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007; 20:571-96; PMID:18070707; http://dx.doi.org/10.1016/j.beha.2007.08.004
22. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5:191-9; PMID:14998494; http://dx.doi.org/10.1016/S1535-6108(04)00019-4
23. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 2007; 139:730-43; PMID:18021088; http://dx.doi.org/10.1111/j.1365- 2141.2007.06873.x
24. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106:296-303; PMID:15755896; http://dx.doi.org/10.1182/ blood-2005-01-0034
25. Chesi M, Bergsagel PL. Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program 2011; 2011:344-53; PMID:22160056; http://dx.doi.org/10.1182/asheducation-2011.1.344
26. Rio-Machin A, Ferreira BI, Henry T, Gomez-Lopez G, Agirre X, Alvarez S, Rodriguez-Perales S, Prosper F, Calasanz MJ, Martinez J, et al. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia 2013; 27:925-31; PMID:23174883; http://dx.doi.org/10.1038/leu.2012.302
27. Li Z, Jiao X, Wang C, Shirley LA, Elsaleh H, Dahl O, Wang M, Soutoglou E, Knudsen ES, Pestell RG. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res 2010; 70:8802-11; PMID:20940395; http://dx.doi.org/10.1158/0008-5472.CAN-10-0312
28. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122:3456-63; PMID:23023717; http://dx.doi.org/10.1172/JCI61188
29. Gabrea A, Bergsagel PL, Chesi M, Shou Y, Kuehl WM. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell 1999; 3:119-23; PMID:10024885; http://dx.doi.org/10.1016/S1097- 2765(00)80180-X
30. Munshi NC, Avet-Loiseau H. Genomics in multiple myeloma. Clin Cancer Res 2011; 17:1234-42; PMID:21411439; http://dx.doi.org/10.1158/1078-0432.CCR-10-1843
31. Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, Kyle RA, Henderson KJ, Van Wier S, Greipp P, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008; 22:2280-4; PMID:18528420; http://dx.doi.org/10.1038/leu.2008.142
32. Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa AM, Voillat L, Wetterwald M, Pegourie B, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 2012; 30:1949-52; PMID:22547600; http://dx.doi.org/10.1200/JCO.2011.36.5726
33. Lode L, Eveillard M, Trichet V, Soussi T, Wuilleme S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traulle C, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 2010; 95:1973-6; PMID:20634494; http://dx.doi.org/10.3324/haematol.2010.023697
34. Pichiorri F, Suh S-S, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr., Hofmainster C, Alder H, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18:367-81; PMID:20951946; http://dx.doi.org/10.1016/j.ccr.2010.09.005
35. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103:3175-84; PMID:15070700; http://dx.doi.org/10.1182/blood-2003-06-2151
36. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al. Frequent engagement of the classical and alternative NFkappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12:115-30; PMID:17692804; http://dx.doi.org/10.1016/ j.ccr.2007.07.004
37. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng W-J, Van Wier S, Tiedemann R, Shi CX, Sebag M, et al. Promiscuous mutations activate the noncanonical NFkappaB pathway in multiple myeloma. Cancer Cell 2007; 12:131-44; PMID:17692805; http://dx.doi.org/10.1016/j.ccr.2007.07.003
38. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 2008; 6:1356-64; PMID:18708367; http://dx.doi.org/10.1158/1541-7786.MCR-08-0108
39. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467-72; PMID:21430775; http://dx.doi.org/10.1038/nature09837
40. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NFkappaB pathway activation in multiple myeloma. Blood 2010; 115:3541-52; PMID:20053756; http://dx.doi.org/10.1182/blood-2009-09- 243535
41. Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R; Intergroupe Francophone du Myelome. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001; 98:3082-6; PMID:11698294; http://dx.doi.org/10.1182/blood. V98.10.3082
42. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25:1026-35; PMID:21468039; http://dx.doi.org/10.1038/leu.2011.53
43. Bergsagel PL, Affer M, Glebov OK, Chen W-DD, Keats JJ, Brents LA, et al. Promiscuous cryptic rearrangements of the MYC locus cis-dysregulate MYC expression and are present in the majority of patients with hyperdiploid myeloma. Blood ASH meeting abstracts 2012. 120:724
44. Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 2008; 2008:25-31; PMID:18647998; http://dx.doi.org/10.1093/jncimonographs/lgn011
45. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120:1067-76; PMID:22498740; http://dx.doi.org/10.1182/blood-2012-01-405985
46. Magrangeas F, Avet-Loiseau H, Gouraud W, Lode L, Decaux O, Godmer P, Garderet L, Voillat L, Facon T, Stoppa AM, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 2013; 27:473-81; PMID:22874878; http://dx.doi.org/10.1038/leu.2012.226
47. Egan JB, Kortuem KM, Kurdoglu A, Izatt T, Aldrich J, Reiman R, Phillips L, Baker A, Shi CX, Schmidt J, et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol 2013; 161:748-51; PMID:23480694; http://dx.doi.org/10.1111/bjh.12291
48. Weston-Bell N, Gibson J, John M, Ennis S, Pfeifer S, Cezard T, Ludwig H, Collins A, Zojer N, Sahota SS. Exome sequencing in tracking clonal evolution in multiple myeloma following therapy. Leukemia 2013; 27:1188-91; PMID:23147253; http://dx.doi.org/10.1038/leu.2012.287
49. Walker BA, Morgan GJ. Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma. Clin Lymphoma Myeloma 2006; 7:186-91; PMID:17229333; http://dx.doi.org/10.3816/CLM.2006.n.057
50. Weinhold N, Johnson DC, Chubb D, Chen B, Forsti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, et al. The CCND1 c.870G A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet 2013; 45:522-5; PMID:23502783; http://dx.doi.org/10.1038/ng.2583
51. Ricke RM, van Deursen JM. Aneuploidy in health, disease, and aging. J Cell Biol 2013; 201:11-21; PMID:23547028; http://dx.doi.org/10.1083/jcb. 201301061
52. Siegel JJ, Amon A. New insights into the troubles of aneuploidy. Annu Rev Cell Dev Biol 2012; 28:189-214; PMID:22804579; http://dx.doi.org/10.1146/ annurev-cellbio-101011-155807
53. Chng WJ, Fonseca R. Centrosomes and myeloma; aneuploidy and proliferation. Environ Mol Mutagen 2009; 50:697-707; PMID:19739237; http://dx.doi.org/10.1002/em.20528
54. Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, Dogan A, Fonseca R. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008; 111:1603-9; PMID:18006703; http://dx.doi.org/10.1182/ blood-2007-06-097774
55. Lindahl T. Instability and decay of the primary structure of DNA. Nature 1993; 362:709-15; PMID:8469282; http://dx.doi.org/10.1038/362709a0
56. Hoeijmakers JHJ. DNA damage, aging, and cancer. N Engl J Med 2009; 361:1475-85; PMID:19812404; http://dx.doi.org/10.1056/NEJMra0804615
57. Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG, Osieka R. DNA methylation changes in multiple myeloma. Leukemia 2004; 18:1687-92; PMID:15318245; http://dx.doi.org/10.1038/sj.leu.2403434
58. Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011; 117:553-62; PMID:20944071; http://dx.doi.org/10.1182/blood-2010-04-279539
59. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gulla AM, Passarino G, et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 2012; 3:1246-58; PMID:23100393
60. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40:179-204; PMID:20965415; http://dx.doi.org/10. 1016/j.molcel.2010.09.019
61. Iyama T, Wilson DM 3rd. DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst) 2013; 12:620-36; PMID:23684800; http://dx.doi.org/10.1016/j.dnarep.2013.04.015
62. Caldecott KW. Single-strand break repair and genetic disease. Nat Rev Genet 2008; 9:619-31; PMID:18626472
63. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001; 1:22-33; PMID:11900249; http://dx.doi.org/10.1038/35094000
64. Hanawalt PC, Spivak G. Transcription-coupled DNA repair: two decades of progress and surprises. Nat Rev Mol Cell Biol 2008; 9:958-70; PMID:19023283; http://dx.doi.org/10.1038/nrm2549
65. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006; 7:335-46; PMID:16612326; http://dx.doi.org/10.1038/nrm1907
66. Shaheen M, Allen C, Nickoloff JA, Hromas R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 2011; 117:6074-82; PMID:21441464; http://dx.doi.org/10.1182/blood-2011-01-313734
67. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011; 11:467-80; PMID:21701511; http://dx.doi.org/10.1038/nrc3088
68. Bunting SF, Callen E, Wong N, Chen H-T, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141:243-54; PMID:20362325; http://dx.doi.org/10.1016/j.cell.2010.03.012
69. Chapman JR, Taylor MRG, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 2012; 47:497-510; PMID:22920291; http://dx.doi.org/10.1016/j.molcel.2012.07.029
70. Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F, Bergsagel PL, Wang L, You Z, Lou Z. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011; 470:124-8; PMID:21293379; http://dx.doi.org/10. 1038/nature09658
71. Tang J, Cho NW, Cui G, Manion EM, Shanbhag NM, Botuyan MV, Mer G, Greenberg RA. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat Struct Mol Biol 2013; 20:317-25; PMID:23377543; http://dx.doi.org/10.1038/nsmb.2499
72. Hochegger H, Dejsuphong D, Fukushima T, Morrison C, Sonoda E, Schreiber V, Zhao GY, Saberi A, Masutani M, Adachi N, et al. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J 2006; 25:1305-14; PMID:16498404; http://dx.doi.org/10.1038/sj.emboj.7601015
73. Adamo A, Collis SJ, Adelman CA, Silva N, Horejsi Z, Ward JD, Martinez-Perez E, Boulton SJ, La Volpe A. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. Mol Cell 2010; 39:25-35; PMID:20598602; http://dx.doi.org/10.1016/j.molcel.2010.06.026
74. Pace P, Mosedale G, Hodskinson MR, Rosado IV, Sivasubramaniam M, Patel KJ. Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. Science 2010; 329:219-23; PMID:20538911; http://dx.doi.org/10.1126/science. 1192277
75. Lieber MR. NHEJ and its backup pathways in chromosomal translocations. Nat Struct Mol Biol 2010; 17:393-5; PMID:20368722; http://dx.doi.org/10.1038/ nsmb0410-393
76. West SC. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 2003; 4:435-45; PMID:12778123; http://dx.doi.org/10.1038/ nrm1127
77. Hartlerode AJ, Scully R. Mechanisms of doublestrand break repair in somatic mammalian cells. Biochem J 2009; 423:157-68; PMID:19772495; http://dx.doi.org/10.1042/BJ20090942
78. Bothmer A, Robbiani DF, Feldhahn N, Gazumyan A, Nussenzweig A, Nussenzweig MC. 53BP1 regulates DNA resection and the choice between classical and alternative end joining during class switch recombination. J Exp Med 2010; 207:855-65; PMID:20368578; http://dx.doi.org/10.1084/jem.20100244
79. Williams HL, Gottesman ME, Gautier J. Replicationindependent repair of DNA interstrand crosslinks. Mol Cell 2012; 47:140-7; PMID:22658724
80. Wang Y, Leung JW, Jiang Y, Lowery MG, Do H, Vasquez KM, Chen J, Wang W, Li L. FANCM and FAAP24 maintain genome stability via cooperative as well as unique functions. Mol Cell 2013; 49:997-1009; PMID:23333308; http://dx.doi.org/10.1016/j.molcel.2012.12.010
81. Kim N, Jinks-Robertson S. Transcription as a source of genome instability. Nat Rev Genet 2012; 13:204-14; PMID:22330764
82. Knipscheer P, Raschle M, Smogorzewska A, Enoiu M, Ho TV, Scharer OD, Elledge SJ, Walter JC. The Fanconi anemia pathway promotes replicationdependent DNA interstrand cross-link repair. Science 2009; 326:1698-701; PMID:19965384; http://dx.doi.org/10.1126/science.1182372
83. Constantinou A. Rescue of replication failure by Fanconi anaemia proteins. Chromosoma 2012; 121:21-36; http://dx.doi.org/10.1007/s00412-011-0349- 2
84. Hayden PJ, Tewari P, Morris DW, Staines A, Crowley D, Nieters A, Becker N, de Sanjose S, Foretova L, Maynadie M, et al. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Hum Mol Genet 2007; 16:3117-27; PMID:17901044; http://dx.doi.org/10.1093/hmg/ddm273
85. Roddam PL, Rollinson S, O'Driscoll M, Jeggo PA, Jack A, Morgan GJ. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet 2002; 39:900-5; PMID:12471202; http://dx.doi.org/10.1136/jmg.39.12. 900
86. Roddam PL, Allan JM, Dring AM, Worrillow LJ, Davies FE, Morgan GJ. Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myeloma. Br J Haematol 2010; 149:258-62; PMID:20148879; http://dx.doi.org/10.1111/j.1365-2141.2010.08088.x
87. Calimeri T, Fulcineti M, Lin J, Samur MK, Calkins AS, Vahia AV, et al. Aberrant non-homologous end joining in multiple myeloma: a role in genomic instability and as a potential prognostic marker. Blood ASH meeting abstracts 2012. 120:2932
88. Tai YT, Teoh G, Lin B, Davies FE, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Podar K, et al. Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol 2000; 165:6347-55; PMID:11086072
89. Kato M, Iida S, Komatsu H, Ueda R. Lack of Ku80 alteration in multiple myeloma. Jpn J Cancer Res 2002; 93:359-62; PMID:11985783; http://dx.doi.org/10. 1111/j.1349-7006.2002.tb01264.x
90. Han Z, Johnston C, Reeves WH, Carter T, Wyche JH, Hendrickson EA. Characterization of a Ku86 variant protein that results in altered DNA binding and diminished DNA-dependent protein kinase activity. J Biol Chem 1996; 271:14098-104; PMID:8662896; http://dx.doi.org/10.1074/jbc.271.24.14098
91. Lanuszewska J, Widłak P. The truncation of Ku86 in human lymphocytes. Cancer Lett 2004; 205:197-205; PMID:15036652; http://dx.doi.org/10. 1016/j.canlet.2003.10.016
92. Gullo CA, Ge F, Cow G, Teoh G. Ku86 exists as both a full-length and a protease-sensitive natural variant in multiple myeloma cells. Cancer Cell Int 2008; 8:4; PMID:18442416; http://dx.doi.org/10.1186/1475-2867-8-4
93. Yang C, Betti C, Singh S, Toor A, Vaughan A. Impaired NHEJ function in multiple myeloma. Mutat Res 2009; 660:66-73; PMID:19028508; http://dx.doi.org/ 10.1016/j.mrfmmm.2008.10.019
94. Keats JJ, Reiman T, Belch AR, Pilarski LM. Ten years and counting: so what do we know about t(4;14) (p16;q32) multiple myeloma. Leuk Lymphoma 2006; 47:2289-300; PMID:17107900; http://dx.doi.org/10.1080/10428190600822128
95. Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 2009; 113:2290-7; PMID:19050310; http://dx.doi.org/10.1182/blood-2007-05-089193
96. Mah L-J, El-Osta A, Karagiannis TC. gamma-H2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010; 24:679-86; PMID:20130602; http://dx.doi.org/10.1038/leu.2010.6
97. Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ, Dispenzieri A, Jelinek DF. Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia 2011; 25:1344-53; PMID:21566653; http://dx.doi.org/10.1038/leu.2011.94
98. Volcic M, Karl S, Baumann B, Salles D, Daniel P, Fulda S, Wiesmuller L. NFκB regulates DNA doublestrand break repair in conjunction with BRCA1-CtIP complexes. Nucleic Acids Res 2012; 40:181-95; PMID:21908405; http://dx.doi.org/10.1093/nar/gkr687
99. Janssens S, Tschopp J. Signals from within: the DNAdamage-induced NFkappaB response. Cell Death Differ 2006; 13:773-84; PMID:16410802; http://dx.doi.org/10.1038/sj.cdd.4401843
100. Miyamoto S. Nuclear initiated NFκB signaling: NEMO and ATM take center stage. Cell Res 2011; 21:116-30; PMID:21187855; http://dx.doi.org/10. 1038/cr.2010.179
101. Habraken Y, Piette J. NFkappaB activation by doublestrand breaks. Biochem Pharmacol 2006; 72:1132-41; PMID:16965765; http://dx.doi.org/10.1016/j.bcp. 2006.07.015
102. Stilmann M, Hinz M, Arslan SC, Zimmer A, Schreiber V, Scheidereit C. A nuclear poly(ADPribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol Cell 2009; 36:365-78; PMID:19917246; http://dx.doi.org/10.1016/j.molcel.2009.09.032
103. Dumontet C, Landi S, Reiman T, Perry T, Plesa A, Bellini I, Barale R, Pilarski LM, Troncy J, Tavtigian S, et al. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplant 2010; 45:1316-24; PMID:19966851; http://dx.doi.org/10.1038/bmt.2009. 335
104. Ushie C, Saitoh T, Iwasaki A, Moriyama N, Murakami H. The polymorphisms of base excision repair genes influence the prognosis of multiple myeloma. Blood ASH meeting abstracts 2012; 120
105. Yang Z-Z, Chen X-H, Wang D. Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector. Clin Lymphoma Myeloma 2007; 7:296-304; PMID:17324338; http://dx.doi.org/10.3816/CLM.2007.n.006
106. de Larrea CF, Navarro A, Tovar N, Pedrosa F, Diaz T, Cibeira MAT, et al. Impact of single nucleotide polymorphisms in genes involved in DNA repair and drug metabolism on survival after autologous stem cell transplantation in patients with multiple myeloma. Blood ASH meeting abstracts 2012; 120:2934
107. Episkopou H, Kyrtopoulos SA, Sfikakis PP, Fousteri M, Dimopoulos MA, Mullenders LHF, Souliotis VL. Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts. Cancer Res 2009; 69:4424-33; PMID:19417135; http://dx.doi.org/10.1158/0008-5472.CAN-08-3489
108. Martin P, Santon A, Garcia-Cosio M, Bellas C. hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies. Mod Pathol 2006; 19:914-21; PMID:16607377; http://dx.doi.org/10.1038/modpathol.3800590
109. Kotoula V, Hytiroglou P, Kaloutsi V, Barbanis S, Kouidou S, Papadimitriou CS. Mismatch repair gene expression in malignant lymphoproliferative disorders of B-cell origin. Leuk Lymphoma 2002; 43:393-9; PMID:11999575; http://dx.doi.org/10.1080/10428190290006215
110. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, Kozarewa I, Gonzalez D, Lord CJ, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 2012; 120:1077-86; PMID:22573403; http://dx.doi.org/10. 1182/blood-2012-03-412981
111. Osborne MR, Wilman DE, Lawley PD. Alkylation of DNA by the nitrogen mustard bis(2-chloroethyl) methylamine. Chem Res Toxicol 1995; 8:316-20; PMID:7766817; http://dx.doi.org/10.1021/tx00044a018
112. Muniandy PA, Liu J, Majumdar A, Liu S-T, Seidman MM. DNA interstrand crosslink repair in mammalian cells: step by step. Crit Rev Biochem Mol Biol 2010; 45:23-49; PMID:20039786; http://dx.doi.org/10.3109/10409230903501819
113. Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002; 100:224-9; PMID:12070031; http://dx.doi.org/10.1182/blood. V100.1.224
114. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58; PMID:11902585; http://dx.doi.org/10.1038/nrc7061
115. Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 2003; 21:4239-47; PMID:14615454; http://dx.doi.org/10.1200/JCO.2003. 06.001
116. Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos E, Kyrtopoulos SA, Sfikakis PP. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica 2007; 92:1505-12; PMID:18024399; http://dx.doi.org/10.3324/ haematol.11435
117. Vangsted A, Gimsing P, Klausen TW, Nexo BA, Wallin H, Andersen P, Hokland P, Lillevang ST, Vogel U. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007; 120:1036-45; PMID:17131345; http://dx.doi.org/10.1002/ijc.22411
118. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005; 106:698-705; PMID:15802532; http://dx.doi.org/10.1182/blood-2004-11-4286
119. Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, et al. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009; 69:9367-75; PMID:19934314; http://dx.doi.org/10.1158/0008-5472.CAN-09-2616
120. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101:1053-62; PMID:12393461; http://dx.doi.org/10.1182/blood-2002-05-1320
121. Xiao H, Xiao Q, Zhang K, Zuo X, Shrestha UK. Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann Hematol 2010; 89:399-404; PMID:19756599; http://dx.doi.org/10. 1007/s00277-009-0831-6
122. Pan Y, Gao Y, Chen L, Gao G, Dong H, Yang Y, Dong B, Chen X. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res 2011; 17:3248-58; PMID:21288924; http://dx.doi.org/10.1158/1078-0432.CCR-10-0890
123. Katayama M, Kawaguchi T, Berger MS, Pieper RO. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 2007; 14:548-58; PMID:16946731; http://dx.doi.org/10.1038/sj.cdd.4402030
124. Couve S, Mace-Aime G, Rosselli F, Saparbaev MK. The human oxidative DNA glycosylase NEIL1 excises psoralen-induced interstrand DNA cross-links in a three-stranded DNA structure. J Biol Chem 2009; 284:11963-70; PMID:19258314; http://dx.doi.org/10.1074/jbc.M900746200
125. McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM 3rd. Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res 2009; 7:897-906; PMID:19470598; http://dx.doi.org/10.1158/1541-7786.MCR-08-0519
126. Sousa MML, Zub KA, Aas PA, Hanssen-Bauer A, Demirovic A, Sarno A, Tian E, Liabakk NB, Slupphaug G. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells. PLoS One 2013; 8:e55493; PMID:23405159; http://dx.doi.org/10.1371/journal.pone. 0055493
127. Crawford LJA, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TCM, Irvine AE. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006; 66:6379-86; PMID:16778216; http://dx.doi.org/10.1158/0008-5472.CAN-06-0605
128. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2011; 2:209-21; PMID:21444945
129. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006; 46:189-213; PMID:16402903; http://dx.doi.org/10.1146/annurev.pharmtox.46.120604.141300
130. Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 2007; 67:7395-405; PMID:17671210; http://dx.doi.org/10.1158/0008-5472.CAN-07-1015
131. Murakawa Y, Sonoda E, Barber LJ, Zeng W, Yokomori K, Kimura H, Niimi A, Lehmann A, Zhao GY, Hochegger H, et al. Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res 2007; 67:8536-43; PMID:17875693; http://dx.doi.org/10.1158/0008-5472.CAN-07-1166
132. Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, Duggan P, Tassone P, Mansoor A, Stewart DA, et al. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood 2011; 118:6368-79; PMID:21917757; http://dx.doi.org/10.1182/blood-2011-06-363911
133. Roussel M, Moreau P, Huynh A, Mary J-Y, Danho C, Caillot D, Hulin C, Fruchart C, Marit G, Pegourie B, et al.; Intergroupe Francophone du Myelome (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010; 115:32-7; PMID:19884643; http://dx.doi.org/10.1182/blood-2009-06-229658
134. Steele JM. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma. J Oncol Pharm Pract 2013; PMID:23292972; http://dx.doi.org/10.1177/1078155212470388
135. Wang Q-E, Wani MA, Chen J, Zhu Q, Wani G, El-Mahdy MA, Wani AA. Cellular ubiquitination and proteasomal functions positively modulate mammalian nucleotide excision repair. Mol Carcinog 2005; 42:53-64; PMID:15547920; http://dx.doi.org/10.1002/mc.20065
136. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327:1345-50; PMID:20223979; http://dx.doi.org/10.1126/science.1177319
137. Zhu Y-X, Braggio E, Shi C-X, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118:4771-9; PMID:21860026; http://dx.doi.org/10.1182/blood-2011-05-356063
138. Moalli PA, Pillay S, Weiner D, Leikin R, Rosen ST. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood 1992; 79:213-22; PMID:1728309
139. Nojima M, Maruyama R, Yasui H, Suzuki H, Maruyama Y, Tarasawa I, Sasaki Y, Asaoku H, Sakai H, Hayashi T, et al. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res 2009; 15:4356-64; PMID:19549772; http://dx.doi.org/10.1158/1078-0432.CCR-08-3336
140. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringarpure R, et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 2003; 102:3379-86; PMID:12855565; http://dx.doi.org/10.1182/ blood-2003-05-1417
141. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103:3148-57; PMID:15070697; http://dx.doi.org/10.1182/blood-2003-06-1984
142. Tai Y-T, Anderson KC. Bruton's tyrosine kinase: oncotarget in myeloma. Oncotarget 2012; 3:913-4; PMID:22989914
143. Cibeira MT, de Larrea CF, Navarro A, Diaz T, Fuster D, Tovar N, Rosinol L, Monzo M, Blade J. Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Leuk Res 2011; 35:1178-83; PMID:21435719; http://dx.doi.org/10.1016/j.leukres.2011.02.009
144. Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy JD Jr. Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res 2008; 14:4821-9; PMID:18676754; http://dx.doi.org/10.1158/1078-0432.CCR-07-4568
145. Barrera LN, Rushworth SA, Bowles KM, MacEwan DJ. Bortezomib induces heme oxygenase-1 expression in multiple myeloma. Cell Cycle 2012; 11:2248-52; PMID:22617388; http://dx.doi.org/10.4161/cc.20343
146. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481:287-94; PMID:22258607; http://dx.doi.org/10.1038/nature10760
147. Smith J, Tho LM, Xu N, Gillespie DA. Chapter 3-The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer. 1st ed. Elsevier Inc; 2010.
148. Pei X-Y, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, Felthousen J, Almenara JA, Kramer LB, Dent P, et al. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood 2011; 118:5189-200; PMID:21911831; http://dx.doi.org/10.1182/ blood-2011-02-339432
149. Smith J, Tho LM, Xu N, Gillespie DA. Chapter 3-The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer. 1st ed. Elsevier Inc; 2010.
150. Landau HJ, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, Jhanwar SC, Nimer SD, Schwartz GK. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther 2012; 11:1781-8; PMID:22653969; http://dx.doi.org/10.1158/1535-7163.MCT- 11-0949
151. Caraux A, Vincent L, Bouhya S, Quittet P, Moreaux J, Requirand G, Veyrune JL, Olivier G, Cartron G, Rossi JF, et al. Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? Oncotarget 2012; 3:1335-47; PMID:23154454